Serum Levels of Testosterone in Patients with Poly-cythemia Vera by H Fujita et al.
Open Journal of Blood Diseases, 2016, 6, 17-22 
Published Online June 2016 in SciRes. http://www.scirp.org/journal/ojbd 
http://dx.doi.org/10.4236/ojbd.2016.62004   
How to cite this paper: Fujita, H., Ohwada, A. and Nishimura, S. (2016) Serum Levels of Testosterone in Patients with Poly-
cythemia Vera. Open Journal of Blood Diseases, 6, 17-22. http://dx.doi.org/10.4236/ojbd.2016.62004  
 
 
Serum Levels of Testosterone in Patients 
with Polycythemia Vera 
Hiroshi Fujita1, Akira Ohwada2, Shigeko Nishimura1 
1Department of Transfusion Medicine, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan 
2Department of Internal Medicine, Tokyo Metropolitan Bokutoh Hospital, Tokyo, Japan 
 
 
Received 28 July 2016; accepted 13 August 2016; published 16 August 2016 
 
Copyright © 2016 by authors and Scientific Research Publishing Inc. 







Despite its association with vascular events such as myocardial and cerebral infarction, polycy-
themia vera (PV) is characterized by low serum total cholesterol levels. Because several sex hor-
mones are derived from cholesterol, statins may induce hypogodanism in male patients. There-
fore, we assessed the relationship between serum total cholesterol and sex hormone levels ac-
cording to gender. Medical records of 41 patients with erythrocytosis (hemoglobin concentrations: 
men >18.5 g/dL; women >16.5 g/dL) collected between August 2005 and December 2014 were re-
viewed for patient age, and gender, as well as clinical hematology, biochemistry, and endocrinol-
ogy laboratory findings. Serum levels of testosterone were lower in men with PV than in patients 
with reactive erythrocytosis (RE) (PV: 385 ± 78 ng/mL versus RE: 529 ± 46 ng/mL). However, se-
rum levels of testosterone in women with PV were comparable to those in patients in the non- 
erythrocytic group (PV: 20.5 ± 3.5 ng/mL versus non-erythrocytic group: 21.0 ± 4.3 ng/mL). Serum 
levels of testosterone were not related to serum levels of cholesterol. Therefore, we speculated 
that lower testosterone levels were not due to lower serum levels of cholesterol, a known adverse 
effect of statin. In conclusion, we report for the first time that serum levels of testosterone were 
lower in male PV patients than in those with RE; however, serum levels of testosterone in female 
patients with PV were not lower. 
 
Keywords 




Because several sex hormones are derived from cholesterol, statins may induce hypogodanism such as erectile 
dysfunction in male patients through severe hypocholesterolemia [1] [2]. Although some types of statins have 
been shown to improve erectile dysfunction [3] [4], their effects were not due to sex hormone production. Be-




cause erectile dysfunction is often associated with endothelial dysfunction, statins may improve endothelial 
function by reducing serum cholesterol levels. 
Moreover, statins also inhibit testosterone synthesis in animal experiments [5]. Statins significantly reduced 
luteinizing hormone (LH)-stimulated testosterone production in rat Leydig cells, suggesting two possible me-
chanisms by which statins might induce decreased testosterone levels. First, statins may reduce serum levels of 
testosterone due to hypocholesterolemia [1] [2]. Second, statins may inhibit testosterone synthesis [5]. 
However, we previously reported that serum levels of total cholesterol, low-density lipoprotein cholesterol, 
and apolipoprotein B were significantly lower in patients with polycythemia vera (PV) than in those with reac-
tive erythrocytosis (RE) without the Janus Kinase 2 (JAK2) V167F gene mutation [6]. PV is classified as a 
myeloproliferative neoplasm and typically occurs in people 60 - 79 years of age. Thrombotic events such as 
myocardial infarction, cerebral infarction, and deep vein thrombosis are the main clinical complications of PV 
[7]. The JAK2 gene mutation has become an important criterion for the diagnosis of PV as the JAK2 V617F 
mutation is observed in approximately 95% of patients with PV [8]. However, other mutations involving JAK2 
exon 12, the Von Hippel-Lindau Tumor Suppressor (VHL) gene, and hypoxia-inducible factor-2 are also asso-
ciated with idiopathic erythrocytosis [9] [10].  
Thus, we revisited the relationship between serum total cholesterol levels and sex hormones, especially tes-
tosterone, from the viewpoints of gender differences. We reported that serum levels of testosterone in male pa-
tients with PV were lower than those in patients with RE, while serum levels of testosterone in female patients 
with PV were almost equal to those in non-erythrocytic females, in spite of the presence of hypocholesterolemia 
in female patients with PV. 
2. Patients and Methods 
2.1. Patients 
Tokyo Metropolitan Bokutoh Hospital is located in eastern Tokyo. We retrospectively reviewed the medical 
records of 34 patients at this hospital with erythrocytosis (hemoglobin [Hb]: men, >18.5 g/dL; women, >16.5 
g/dL), collected between August 2005 and December 2014. The medical records were reviewed for patient age, 
gender, and laboratory test results. Patients taking medications such as statins for hypercholesterolemia were ex-
cluded from this study. Male and female patients were divided into PV and reactive erythrocytosis (RE) groups 
according to World Health Organization (WHO) classifications. The non-erythrocytic subjects included both 
medically healthy workers under 65 years of age and hypertensive patients without hyperlipidemia >65 years of 
age (N = 18). All subjects provided informed consent for their participation in the study, and the study design 
was approved by the ethics review board of our institution. 
2.2. Methods 
Venous blood was collected into evacuated tubes in order to measure the sex hormone profile (testosterone, free 
testosterone, estrogen, follicle-stimulating hormone [FSH], LH, and corticosteroids) during initial phlebotomy 
tests in our department. Serum samples were collected, frozen immediately, and stored at −80˚C until further 
analysis. The serum hormone profiles were measured by the BML company (Tokyo, Japan). 
2.3. Statistical Analyses 
We compared the differences between the PV and reactive erythrocytosis groups, or non-erythrocytosis groups 
by Wilcoxon’s analysis. Data were expressed as group means ± standard errors of the mean or medians with in-
terquartile ranges. All statistical calculations were performed using JMP version 8.0 (SAS Institute, Inc., Cary, 
NC), and significance was defined as p < 0.05. 
The correlations between serum levels of cholesterol and sex hormones were assessed by linear regression 
analysis. For the linear regression analysis results, significance was defined as p < 0.0001. 
3. Results 
3.1. Sex Hormone Levels in Male Patients with PV 
Of 41 patients with erythrocytosis, 21 were diagnosed with PV. The other 13 patients with erythrocytosis tested 




negative for the JAK2 V617F mutation and were thus not diagnosed with PV (reactive erythrocytosis, RE). The 
patients with RE were all male (N = 13), and seven male patients were diagnosed with PV. We compared the 
clinical profiles, hematology, biochemistry (cholesterol and albumin), and sex hormone findings among male 
patients with PV (N = 7), non-PV erythrocytosis (N = 13) and non-erythrocytosis (N = 11), as shown in Table 1. 
Male patients with PV had significantly lower body mass index (BMI) than did those with RE. Serum cholester-
ol levels in patients with PV were lower than those with RE and those in the non-erythrocytic group. Among sex 
hormones, serum testosterone and estradiol levels were significantly lower in patients with PV than in patients 
with RE, as shown in Table 1. 
There was no correlation between serum levels of cholesterol and sex hormones (testosterone: r2 = 0.08197, p 
= 0.1250 and estradiol: r2 = 0.08952, p = 0.1082). 
3.2. Sex Hormones in Female Patients with PV  
Among the female patients in this study, 11 had PV, and none had RE. Therefore, we compared the clinical, 
hematology, cholesterol, and sex hormone profiles between the PV (N = 14) and non-erythrocytosis (N = 7) 
groups. There were no differences in BMI or sex hormone levels between the PV and non-erythrocytosis groups, 
although serum cholesterol levels in patients with PV were significantly lower than those in patients with non- 
erythrocytosis (Table 2). 
 
Table 1. Clinical profiles, hematology, serum cholesterol and sex hormone levels in male patients with erythrocytosis. 
 Polycythemia vera N = 7 
Reactive erythrocytosis 
N = 13 
Non-erythrocytosis 
N = 11 
Clinical profile    
Age 60 (4) 64 (3) 67 (2) 
Height (cm) 168 (3) 164 (3) 161 (2) 
Weight (kg) 61 (4) 67 (4) 60 (3) 
Body mass index 21 (1)* 25 (1) 23 (1) 
Hematology    
Red blood cells (×104/μL) 717 (36)*# 586 (12) 449 (14) 
Hemoglobin (g/dL) 19.5 (0.4)# 19.7 (0.3)# 14.2 (0.3) 
Hematocrit (%) 59.3 (1.3)# 57.6 (1.1)# 42.5 (0.9) 
Mean Corpuscular volume (fL) 83.8 (3.5)*# 98.4 (1.5) 94.8 (2.1) 
Platelet (×104/μL) 36.7 (7.1)*# 16.5 (0.8) 20.4 (1.2) 
White blood cells (/μL) 17,257(4491)*# 6,408(309) 5,727(415) 
Biochemistry    
Total cholesterol (mg/dL) 163 (12)# 186 (8) 190 (9) 
Serum albumin (g/dL) 4.5 (0.1) 4.4 (0.1) 4.3 (0.1) 
Sex hormone profile    
LH (mIU/mL) 5.9 (1.7) 7.2 (0.8) 6.9 (1.4) 
FSH (mIU/mL) 16.7 (4.5) 9.1 (1.0) 14.1 (3.6) 
Testosterone (ng/mL) 385 (78)* 529 (46) 570 (55) 
Free testosterone (pg/mL) 8.0 (2.0) 8.5 (0.8) 7.5 (1.0) 
Estradiol (pg/mL) 17.1 (4.1)*# 28.5 (2.5) 28.4 (3.0) 
Cortisol (μg/dL) 13.5 (3.7) 12.0 (1.1) 13.1 (1.0) 
Data are shown as means (standard errors). *: p < 0.05 vs. reactive erythrocytosis; #: p < 0.05 vs. non-polycythemic subjects; Reference value for sex 
hormones in men; Luteinizing hormone: 0.8 - 5.7 mIU/mL; Follicle-stimulating hormone: 2.0 - 8.3 mIU/mL Testosterone: 229 - 1,039 ng/dL; Free 
testosterone: 50 - 59 yrs: 6.9 - 18.4, 60 - 69 yrs: 5.4 - 16.7, 70 - 79 yrs: 4.5 - 18.8; Estradiol: 19 - 51 pg/mL; Cortisol: 4.5 - 21.1 μg/dL. 




Table 2. Clinical profiles, hematology, serum cholesterol, and sex hormone levels in female patients with erythrocytosis. 
 Polycythemia vera N = 14 
Non-erythrocytosis 
N = 7 
Clinical profile   
Age 70 (2) 74 (2) 
Height (cm) 151 (8) 154 (5) 
Weight (kg) 54 (3) 50 (2) 
Body mass index 23 (1) 21 (1) 
Hematology   
Red blood cells (×104/μL) 726 (21)# 410 (14) 
Hemoglobin (g/dL) 18.2 (0.5)# 13.0 (13.6) 
Hematocrit (%) 57.4 (1.0)# 39.0 (0.9) 
Mean Corpuscular volume (fL) 80 (3)# 95 (2) 
Platelet (×104/μL) 47.0 (4.8)# 21.0 (2.1) 
White blood cells (/μL) 15,350 (1,858)# 5443 (56) 
Biochemistry   
Total cholesterol (mg/dL) 159 (5)# 193 (10) 
Serum albumin (g/dL) 4.1 (0.1) 4.3 (0.1) 
Sex hormone profile   
LH (mIU/mL) 19.4 (1.4) 19.1 (2.7) 
FSH (mIU/mL) 51.1 (5.9) 46.7 (6.2) 
Testosterone (ng/mL) 20.5 (3.5) 21.0 (4.3) 
Free testosterone (pg/mL) 16.4(6.0) 8.8 (2.2) 
Estradiol (pg/mL) 12.3 (0.7) 15.1 (2.7) 
Cortisol (μg/dL)   
Data are shown as means (standard errors). #: p < 0.05 vs. non-polycythemic subjects; Reference values for sex hormones in women; Luteinizing 
hormone after menopause: 5.7 - 64.3 mIU/mL; Follicle-stimulating hormone after menopause: <157.8 mIU/mL; Testosterone: 33.0 - 126 ng/dL; Es-
tradiol after menopause: <39 pg/mL; Cortisol: 4.5 - 21.1 μg/dL. 
4. Discussion 
4.1. Serum Levels of Cholesterol and Sex Hormones in Patients with PV 
There are two possible mechanisms by which statins might induce lower testosterone levels. First, statins may 
reduce serum testosterone levels via hypocholesterolemia [1] [2]. Serum levels of cholesterol in the male pa-
tients were lower than those in patients with RE and the non-erythrocytic group in this study, as shown in Table 
1. However, lower cholesterol levels were not related to lower hormone (testosterone and estradiol) levels. In 
addition, serum levels of testosterone in female patients with PV were the same as those in the non-erythrocytic 
group, although the serum levels of cholesterol in female patients with PV were lower than those in the non- 
erythrocytic group. These data suggested that lower cholesterol levels were not related to lower testosterone le-
vels. Second, lower LS levels may inhibit testosterone synthesis [5]. However, serum levels of LH and FSH in 
the male patients with PV in this study were not lower than those in the RE and non-erythrocytic groups. There-
fore, it was likely that there was no LH-stimulated testosterone production in male patients with PV. Thus, our 
hypothesis that hypocholesterolemia might induce lower testosterone levels was mistaken.  
4.2. Serum Levels of Testosterone Might Be Down-Regulated by Negative Feedback 
Testosterone itself stimulates erythropoietin production and increases hematocrit [11]. Polycythemia is a known 
adverse effect of testosterone treatment for hypogonadism [12]. Moreover, in the chronic mountain sickness, 
serum testosterone levels increase with high hematocrit [13] [14]. Therefore, one possibility that serum testoste-
rone may be down-regulated by negative feedback system in the male patients with PV, while erythropoietin 




production is down-regulated by negative feedback system in the patients with PV [8]. We previously reported 
that serum levels of granulocyte-colony stimulating factor (G-CSF) in the patients with PV were lower than 
those in patients with with RE [15]. We speculate serum levels of testosterone may be down-regulated as same 
as erythropoietin and G-CSF. However, we do not understand the mechanism by which serum levels of estradiol 
in the male patients with PV were also lower than those in patients with RE. There is a rare case report showing 
the relationship between estrogen and polycythemia [16]. Estrogen is usually produced from testosterone during 
the aromatase activation. Aromatase inhibitors may increase testosterone, resulting from erythrocytosis. In our 
study, lower serum levels of testosterone in the male patients with PV affected lower serum levels of estrogen, 
in spite of the presence of aromatase. 
Typical therapy for elderly patients with PV includes the use of hydroxyurea, which may induce hypogonad-
ism [17]. However, while no patients in our study had hypogonadism, we should be aware of the potential for 
hypogonadism in male patients with PV after administration of hydroxyurea. 
5. Conclusion 
To our knowledge, this is the first study to report that serum levels of testosterone are lower in male PV patients 
than in those with RE. 
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